April 11 - Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, said on Friday that it would be looking to raise as much as $214.3 million through an initial public offering, with a value of about $2.3 billion.
The Berlin biotech startup, which wants to explore the use of psychedelic treatments for mental health disorders, said that it plans to sell about 14.29 million shares priced between $13 and $15 per share. To quote a friend, I have to go back and forth through my life, to try and define the new life...
Christian Angermayer is co-founder of Atai and an advocate for the psychedelic benefits of psilocybin, the active ingredient in so-called magic mushrooms, for the treatment of depression, anxiety and substance use disorders.
The company raised $157 million from investors at a valuation of about $2 billion and was considering floating its shares in the U.S. in May, reported Reuters in March, citing a source close to the matter.
Having been launched in 2018, Atai has so far raised $362.3 million in cash, according to a regulatory filing.
Atai will be listed on the Nasdaq and will trade under the ATAI - ticker symbol.
The major underwriters for the offer were Credit Suisse, Citigroup, Cowen and Berenberg. What happens in your life, which you will never regret.